 SAN DIEGO, Dec. 07, 2020 GLOBE NEWSWIRE -- Kura Oncology, Inc. Nasdaq: KURA, a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell 200,000,000 of shares of its common stock. In connection with the offering, Kura expects to grant the underwriters a 30-day option to purchase up to an additional 30,000,000 of the shares of common stock offered in the public offering. All of the shares in the proposed offering will be offered by Kura. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. 